课题基金 / 基金详情

Gene therapy for rheumatoid arthritis using transduction with angiogenesis inhibitory factor

Gene therapy for rheumatoid arthritis using transduction with angiogenesis inhibitory factor
使用血管生成抑制因子转导治疗类风湿性关节炎的基因疗法
批准号:
15591067
负责人:
NAGASHIMA Masakazu
金额:
$1.54万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

NAGASHIMA Masakazu的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Rheumatoid arthritis(RA) is characterized by serious chronic inflammation in the synovium, synovial cell proliferation, lymphocyte inflammation, and pannus formation, resulting in joint cartilage erosion and bone destruction. A number of angiogenic growth factor are involved in angiogenesis process in the RA joint. We have clarified that the vascular endothelial growth factor(VEGF) and basic-fibroblast growth factor(b-FGF) are expressed and localized in synovial tissues from RA patients and that there expression level is significantly higher than that from osteoarthritis. We investigated whether angiogenic inhibitors regulated the angiogenesis and synovial cell profferation using anti-angiogenic gene therapy. Angiostain is a potent endogenous anti-angiogenic factor that is derived from plasminogen and was originally purified from the serum and urine of mice with primary Lewis lung carcinoma tumors. Purified recombinant angiostatin and vectors carrying the angiostatin expression until h … More ave both been successfully used for inhibition of tumor growth and metastasis in various cancer models. We generated a murine CIA model and examined the utility of the HIV vector containing the gene for murine angiostatin in the treatment of arthritis. HIV vector-mediated expression of angiostatin efficiently inhibits the progression of collagen-induced arthritis. A disadvantage of HIV based vectors is potential pathogenicity of parent virus for human species. Although the recombinant HIV vector was extensively modified to increase the safety, its clinical application is still strictly restricted. Adeno-associated virus(AAV) vectors are nonpathogenic and less immunogenic compared with other types of gene therapy vectors. The AAV genome shows stable persistence in transduced cells and achieves long-term transgene expression. AAV vectors were capable of efficient gene transfer into chondrocytes and synovial cells, and extent of synovial hyperplasia and joint destruction were significantly reduced in the knee joints. Reduction in the number of vessels was confirmed in AAV-Ang treated joints.AAV-vector-mediated the development of collagen-induced arthritis in the treated joint Anti-angiogenic gene therapy using AAV vector may provide a new approach for the effective treatment of RA. Less
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s00296-004-0476-7
发表时间: 2005-09-01
期刊: RHEUMATOLOGY INTERNATIONAL
影响因子: 4
作者: [Kato, K, Miyake, K, Shimada, T]
通讯作者: Shimada, T
DOI: 10.1038/ng1267
发表时间: 2003-12-01
期刊: NATURE GENETICS
影响因子: 30.8
作者: [Tokuhiro, S, Yamada, R, Yamamoto, K]
通讯作者: Yamamoto, K
高橋 央 他: "AAV vectorを用いた関節炎モデルマウスの血管新生抑制遺伝子治療"日本整形外科学会雑誌. 77(8). S995 (2003)
Hiroshi Takahashi 等人:“使用 AAV 载体对关节炎模型小鼠进行血管生成抑制基因治疗”,日本骨科学会杂志 77(8) (2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice.
腺相关病毒载体介导的抗血管生成基因疗法治疗小鼠胶原诱导的关节炎。
DOI: --
发表时间: 2005
期刊: Clinical and Experimental Rheumatology 23(in press)
影响因子: --
作者: [Takahashi H, Kato K, Miyake K, Shimada T et al.]
通讯作者: Shimada T et al.
関節リウマチのサイトカインおよび血管増殖因子抑制効果に関する基礎的研究-サイトカインおよびVEGFアンチセンス療法による新しい治療戦略-
  • 批准号:
    10670433
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $1.92万
  • 财政年份:
    1998
  • 负责人:
    NAGASHIMA Masakazu
  • 依托单位: